Review Article | Published:

Emerging roles of p53 and other tumour-suppressor genes in immune regulation

Nature Reviews Immunology volume 16, pages 741750 (2016) | Download Citation

Abstract

Tumour-suppressor genes are indispensable for the maintenance of genomic integrity. Recently, several of these genes, including those encoding p53, PTEN, RB1 and ARF, have been implicated in immune responses and inflammatory diseases. In particular, the p53 tumour- suppressor pathway is involved in crucial aspects of tumour immunology and in homeostatic regulation of immune responses. Other studies have identified roles for p53 in various cellular processes, including metabolism and stem cell maintenance. Here, we discuss the emerging roles of p53 and other tumour-suppressor genes in tumour immunology, as well as in additional immunological settings, such as virus infection. This relatively unexplored area could yield important insights into the homeostatic control of immune cells in health and disease and facilitate the development of more effective immunotherapies. Consequently, tumour-suppressor genes are emerging as potential guardians of immune integrity.

Key points

  • The role of tumour suppressors in immunity is strongly linked to maintenance of genomic integrity.

  • Impaired expression of tumour suppressor genes such as those that encode p53, retinoblastoma-associated gene 1 (RB1), phosphatase and tensin homologue (PTEN) and ARF results in susceptibility to chronic inflammatory responses triggered by pathogens and environmental stress.

  • The tumour suppressor p53 and its transcriptional targets are involved in crucial aspects of tumour and pathogen immunology and in homeostatic regulation of immune responses. This pathway has an important role in host immunity influencing both innate and adaptive immune responses.

  • A link between the tumour suppressor p53 and immune checkpoint regulators, including programmed cell death 1 (PD1), PD1 ligand 1 (PDL1) and DD1α, has been identified in cancer cells.

  • Several tumour suppressor genes including those encoding p53, ARF, RB1 and PTEN influence T cell fate by modulating the immune synapse through pattern recognition receptors, cytokine production and expression of MHC and co-inhibitory molecules.

  • Tumour suppressor gene function is emerging as a potential 'guardian of immune integrity'.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.

from$8.99

All prices are NET prices.

References

  1. 1.

    & How does multistep tumorigenesis really proceed? Cancer Discov. 5, 22–24 (2015).

  2. 2.

    & Hallmarks of cancer: the next generation. Cell 144, 646–674 (2011).

  3. 3.

    Coming full circle-from endless complexity to simplicity and back again. Cell 157, 267–271 (2014).

  4. 4.

    , & Cancer despite immunosurveillance: immunoselection and immunosubversion. Nat. Rev. Immunol. 6, 715–727 (2006).

  5. 5.

    , & Cancer immunoediting: integrating immunity's roles in cancer suppression and promotion. Science 331, 1565–1570 (2011).

  6. 6.

    , , , & Natural and therapy-induced immunosurveillance in breast cancer. Nat. Med. 21, 1128–1138 (2015).

  7. 7.

    , , & On being less tolerant: enhanced cancer immunosurveillance enabled by targeting checkpoints and agonists of T cell activation. Sci. Transl. Med. 7, 280sr1 (2015).

  8. 8.

    , , , & Immunosurveillance and immunotherapy of tumors by innate immune cells. Curr. Opin. Immunol. 38, 52–58 (2016).

  9. 9.

    & Long story short: 53 mediates innate immunity. Biochim. Biophys. Acta 1865, 220–227 (2016). This study summarizes the coordinated responses of p53 to viral infection, and outlines a model that would explain how p53 evolved to mediate immune surveillance.

  10. 10.

    , , , & Type I interferons in anticancer immunity. Nat. Rev. Immunol. 15, 405–414 (2015).

  11. 11.

    , , , & Metabolic regulation by p53 family members. Cell. Metab. 18, 617–633 (2013).

  12. 12.

    , , & Activation of the tumor suppressor p53 upon impairment of ribosome biogenesis. Biochim. Biophys. Acta 1842, 817–830 (2014).

  13. 13.

    p53 and ribosome biogenesis stress: the essentials. FEBS Lett. 588, 2571–2579 (2014).

  14. 14.

    , & Regulation of cancer metabolism by oncogenes and tumor suppressors. Methods Enzymol. 542, 59–80 (2014).

  15. 15.

    et al. AMP-activated protein kinase induces a p53-dependent metabolic checkpoint. Mol. Cell 18, 283–293 (2005).

  16. 16.

    , & p53 in survival, death and metabolic health: a lifeguard with a licence to kill. Nat. Rev. Mol. Cell. Biol. 16, 393–405 (2015).

  17. 17.

    & p53 Research: the past thirty years and the next thirty years. Cold Spring Harb. Perspect. Biol. 2, a000893 (2010).

  18. 18.

    et al. Serine starvation induces stress and p53-dependent metabolic remodelling in cancer cells. Nature 493, 542–546 (2013).

  19. 19.

    et al. Autophagy regulation by p53. Curr. Opin. Cell Biol. 22, 181–185 (2010).

  20. 20.

    & Blinded by the light: The growing complexity of p53. Cell 137, 413–431 (2009).

  21. 21.

    & p53 and metabolism. Nat. Rev. Cancer 9, 691–700 (2009).

  22. 22.

    & To be, or not to be: functional dilemma of p53 metabolic regulation. Curr. Opin. Oncol. 26, 78–85 (2014).

  23. 23.

    et al. Subtle variations in Pten dose determine cancer susceptibility. Nat. Genet. 42, 454–458 (2010).

  24. 24.

    , , & Inhibition of AMPK and Krebs cycle gene expression drives metabolic remodeling of Pten-deficient preneoplastic thyroid cells. Cancer Res. 73, 5459–5472 (2013).

  25. 25.

    & The PTEN-PI3K pathway: of feedbacks and cross-talks. Oncogene 27, 5527–5541 (2008).

  26. 26.

    , & Caught in the cross fire: 53 in inflammation. Carcinogenesis 35, 1680–1690 (2014).

  27. 27.

    & AMP-activated protein kinase phosphorylates retinoblastoma protein to control mammalian brain development. Dev. Cell 16, 256–270 (2009).

  28. 28.

    et al. Systemic elevation of PTEN induces a tumor-suppressive metabolic state. Cell 149, 49–62 (2012).

  29. 29.

    & New perspective on targeting the tumor suppressor p53 pathway in the tumor microenvironment to enhance the efficacy of immunotherapy. J. Immunother. Cancer 3, 9 (2015).

  30. 30.

    , & The expanding universe of p53 targets. Nat. Rev. Cancer 9, 724–737 (2009).

  31. 31.

    & The multiple connections between pRB and cell metabolism. Curr. Opin. Cell Biol. 25, 735–740 (2013).

  32. 32.

    et al. Requirement for ribosomal protein S6 kinase 1 to mediate glycolysis and apoptosis resistance induced by Pten deficiency. Proc. Natl Acad. Sci. USA 108, 2361–2365 (2011).

  33. 33.

    , , , , & Downmodulation of tumour suppressor p53 by T cell receptor signalling is critical for antigen-specific CD4+T cell responses. Immunity 40, 681–691 (2014).

  34. 34.

    et al. Deletion of Irf5 protects hematopoietic stem cells from DNA damage-induced apoptosis and suppresses γ-irradiation-induced thymic lymphomagenesis. Oncogene 33, 3288–3297 (2014).

  35. 35.

    , , , & Influence of p53 on anti-tumor immunity. Int. J. Oncol. 28, 519–525 (2006).

  36. 36.

    et al. A unique role for p53 in the regulation of M2 macrophage polarization. Cell Death Differ. 22, 1081–1093 (2015).

  37. 37.

    , & Interactions between the tumor suppressor p53 and immune responses. Curr. Opin. Oncol. 25, 85–92 (2013). This review explores the relationship between p53 and the innate immune response with particular emphasis on the TLR pathway and its implications for cancer therapy.

  38. 38.

    , & Dual Role of p53 in innate antiviral immunity. Viruses 2, 298–313 (2010).

  39. 39.

    et al. ARF and p53 coordinate tumor suppression of an oncogenic IFN-β-STAT1-ISG15 signaling axis. Cell Rep. 7, 514–526 (2014).

  40. 40.

    , , , & Isg15 controls p53 stability and functions. Cell Cycle 13, 2200–2210 (2014).

  41. 41.

    & p53 versus ISG15: stop, you're killing me. Cell Cycle 13, 2160–2161 (2014).

  42. 42.

    et al. Identification of the interferon regulatory factor 5 gene (IRF-5) as a direct target for p53. Oncogene 21, 2914–2918 (2002).

  43. 43.

    et al. Transcriptional role of p53 in interferon-mediated antiviral immunity. J. Exp. Med. 205, 1929–1938 (2008). This paper identifies a positive feedback loop between the transcriptional programme of p53 and the induction of type I IFN during viral infection.

  44. 44.

    , & The human TLR innate immune gene family is differentially influenced by DNA stress and p53 status in cancer cells. Cancer Res. 72, 3948–3957 (2012). This work provides evidence that several TLRs are directly transactivated by p53.

  45. 45.

    et al. Integration of interferon-alpha/beta signalling to p53 responses in tumour suppression and antiviral defence. Nature 424, 516–523 (2003). The first identification of crosstalk between p53 and type I IFN. This study provides the first evidence that p53 is transcriptionally activated by IFN in response to both oncogenic stress and viral infection.

  46. 46.

    et al. p53 regulates Toll-like receptor 3 expression and function in human epithelial cell lines. Mol. Cell. Biol. 28, 6557–6567 (2008).

  47. 47.

    et al. Role of IFN regulatory factor 5 transcription factor in antiviral immunity and tumor suppression. Proc. Natl Acad. Sci. USA 104, 3402–3407 (2007).

  48. 48.

    et al. Foxp3 expression in p53-dependent DNA damage responses. J. Biol. Chem. 285, 7995–8002 (2010).

  49. 49.

    et al. Tumor suppressor p53 inhibits systemic autoimmune diseases by inducing regulatory T cells. J. Immunol. 191, 3614–3623 (2013).

  50. 50.

    et al. CD4(+)CD25(+) regulatory T cells resist a novel form of CD28- and Fas-dependent p53-induced T cell apoptosis. J. Immunol. 184, 94–104 (2010).

  51. 51.

    , , & Role of p53 in systemic autoimmune diseases. Crit. Rev. Immunol. 34, 509–516 (2014).

  52. 52.

    et al. p53 in the myeloid lineage modulates an inflammatory microenvironment limiting initiation and invasion of intestinal tumors. Cell Rep. 13, 888–897 (2015).

  53. 53.

    et al. Non-cell-autonomous tumor suppression by p53. Cell 153, 449–460 (2013).

  54. 54.

    & Tumor suppression: 53 alters immune surveillance to restrain liver cancer. Curr. Biol. 23, R527–R530 (2013).

  55. 55.

    , , , & The p53 family: guardians of maternal reproduction. Nat. Rev. Mol. Cell. Biol. 12, 259–265 (2011).

  56. 56.

    et al. Resistance to viral infection of super p53 mice. Oncogene 24, 3059–3562 (2005).

  57. 57.

    et al. Influenza virus infection increases p53 activity: role of p53 in cell death and viral replication. J. Virol. 79, 8802–8811 (2005).

  58. 58.

    et al. p53 serves as a host antiviral factor that enhances innate and adaptive immune responses to influenza A virus. J. Immunol. 187, 6428–6436 (2011). This study provides the first evidence that p53 affects not only innate but also adaptive immune responses.

  59. 59.

    , , , & p53-dependent chemokine production by senescent tumor cells supports NKG2D-dependent tumor elimination by natural killer cells. J. Exp. Med. 210, 2057–2069 (2013).

  60. 60.

    et al. Transcriptional analysis of immune-related gene expression in p53-deficient mice with increased susceptibility to influenza A virus infection. BMC Med. Genom. 8, 52 (2015).

  61. 61.

    & Modulation of the ARF-p53 pathway by the small DNA tumor viruses. Cell Cycle 4, 449–452 (2005).

  62. 62.

    , , , & Cross talk between PML and p53 during poliovirus infection: implications for antiviral defense. J. Virol. 80, 8582–8592 (2006).

  63. 63.

    , , & Assembly and localization of Toll-like receptor signalling complexes. Nat. Rev. Immunol. 14, 546–558 (2014).

  64. 64.

    TLR-dependent T cell activation in autoimmunity. Nat. Rev. Immunol. 11, 807–822 (2011).

  65. 65.

    , & The history of Toll-like receptors — redefining innate immunity. Nat. Rev. Immunol. 13, 453–460 (2013).

  66. 66.

    et al. Human NK cells are alerted to induction of p53 in cancer cells by upregulation of the NKG2D ligands ULBP1 and ULBP2. Cancer Res. 71, 5998–6009 (2011).

  67. 67.

    , , , & Leukocyte marker CD43 promotes cell growth in co-operation with β-catenin in non-hematopoietic cancer cells. Int. J. Oncol. 41, 299–309 (2012).

  68. 68.

    & T cells modulate glycans on CD43 and CD45 during development and activation, signal regulation, and survival. Ann. NY Acad. Sci. 1253, 58–67 (2012).

  69. 69.

    et al. CD43 promotes cell growth and helps to evade FAS-mediated apoptosis in non-hematopoietic cancer cells lacking the tumor suppressors p53 or ARF. Oncogene 27, 1705–1715 (2008).

  70. 70.

    , , & Tumor suppressor p53 down-regulates expression of human leukocyte marker CD43 in non-hematopoietic tumor cells. Int. J. Oncol. 40, 567–576 (2012).

  71. 71.

    et al. Autoimmunity to the p53 protein is a feature of systemic lupus erythematosus (SLE) related to anti-DNA antibodies. J. Autoimmun. 17, 63–69 (2001).

  72. 72.

    et al. The tumour suppressor gene p53 modulates the severity of antigen-induced arthritis and the systemic immune response. Clin. Exp. Immunol. 152, 345–353 (2008).

  73. 73.

    , & Regulatory role of p53 in experimental autoimmune encephalomyelitis. J. Neuroimmunol. 135, 29–37 (2003).

  74. 74.

    et al. Regulation of arthritis by p53: critical role of adaptive immunity. Arthritis Rheum. 52, 1876–1884 (2005).

  75. 75.

    et al. Regulation of joint destruction and inflammation by p53 in collagen-induced arthritis. Am. J. Pathol. 160, 123–130 (2002).

  76. 76.

    et al. Regional analysis of p53 mutations in rheumatoid arthritis synovium. Proc. Natl Acad. Sci. USA 99, 10025–10030 (2002).

  77. 77.

    et al. Antibodies against p53 in sera from patients with systemic lupus erythematosus and other rheumatic diseases. Arthritis Rheum. 40, 980–982 (1997).

  78. 78.

    , , & Over-expression of TATA binding protein (TBP) and p53 and autoantibodies to these antigens are features of systemic sclerosis, systemic lupus erythematosus and overlap syndromes. Clin. Exp. Immunol. 136, 574–584 (2004).

  79. 79.

    et al. Anti-p53 autoantibody in systemic sclerosis: association with limited cutaneous systemic sclerosis. J. Rheumatol. 35, 451–457 (2008).

  80. 80.

    et al. p53 autoantibodies in patients with autoimmune diseases: a quantitative approach. Autoimmunity 31, 229–235 (1999).

  81. 81.

    et al. Anti-p53 antibodies in patients with dermatomyositis/polymyositis. Clin. Rheumatol. 26, 1328–1331 (2007).

  82. 82.

    et al. The cell cycle inhibitor p21 controls T-cell proliferation and sex-linked lupus development. Nat. Med. 6, 171–176 (2000).

  83. 83.

    et al. Mice lacking the p53-effector gene Gadd45a develop a lupus-like syndrome. Immunity 16, 499–508 (2002).

  84. 84.

    et al. Role of cyclin kinase inhibitor p21 in systemic autoimmunity. J. Immunol. 167, 4067–4074 (2001).

  85. 85.

    , & Interferons and their stimulated genes in the tumor microenvironment. Semin. Oncol. 41, 156–173 (2014).

  86. 86.

    et al. Effect of p53 status and STAT1 on chemotherapy-induced, Fas-mediated apoptosis in colorectal cancer. Cancer Res. 65, 8951–8960 (2005).

  87. 87.

    et al. Identification of a novel p53-dependent activation pathway of STAT1 by antitumour genotoxic agents. Cell Death Differ. 15, 376–385 (2008).

  88. 88.

    et al. p53 and NF-κB coregulate proinflammatory gene responses in human macrophages. Cancer Res. 74, 2182–2192 (2014).

  89. 89.

    & Modulation of the human interleukin-6 promoter (IL-6) and transcription factor C/EBP β (NF-IL6) activity by p53 species. J. Biol. Chem. 268, 15096–15100 (1993).

  90. 90.

    , & Repression of the interleukin 6 gene promoter by p53 and the retinoblastoma susceptibility gene product. Proc. Natl Acad. Sci. USA 88, 7605–7609 (1991).

  91. 91.

    , & Inflammation and p53: a tale of two stresses. Genes Cancer 2, 503–516 (2011).

  92. 92.

    et al. p53 is a suppressor of inflammatory response in mice. FASEB J. 19, 1030–1032 (2005).

  93. 93.

    et al. p53 controls autoimmune arthritis via STAT-mediated regulation of the Th17 cell/Treg cell balance in mice. Arthritis Rheum. 65, 949–959 (2013).

  94. 94.

    , , , & Tumor suppressor p53 inhibits autoimmune inflammation and macrophage function. Diabetes 54, 1423–1428 (2005).

  95. 95.

    & Phagocytosis of apoptotic cells in homeostasis. Nat. Immunol. 16, 907–917 (2015).

  96. 96.

    & Clearance of apoptotic cells: implications in health and disease. J. Cell Biol. 189, 1059–1070 (2010).

  97. 97.

    & Programmed cell death in animal development and disease. Cell 147, 742–758 (2011).

  98. 98.

    Apoptosis and autoimmune diseases. Ann. NY Acad. Sci. 1209, 10–16 (2010).

  99. 99.

    , & Autoimmunity and the clearance of dead cells. Cell 140, 619–630 (2010).

  100. 100.

    et al. TIM-1 and TIM-4 glycoproteins bind phosphatidylserine and mediate uptake of apoptotic cells. Immunity 27, 927–940 (2007).

  101. 101.

    & Do not let death do us part: 'find-me' signals in communication between dying cells and the phagocytes. Cell Death Differ. 23, 979–989 (2016).

  102. 102.

    & Apoptotic cell recognition receptors and scavenger receptors. Immunol. Rev. 269, 44–59 (2016).

  103. 103.

    & Clearing the dead: apoptotic cell sensing, recognition, engulfment, and digestion. Cold Spring Harb. Perspect. Biol. 5, a008748 (2013).

  104. 104.

    et al. Identification of Tim4 as a phosphatidylserine receptor. Nature 450, 435–439 (2007).

  105. 105.

    et al. T and B cell hyperactivity and autoimmunity associated with niche-specific defects in apoptotic body clearance in TIM-4-deficient mice. Proc. Natl Acad. Sci. USA 107, 8706–8711 (2010).

  106. 106.

    & Dissecting p53-dependent apoptosis. Cell Death Differ. 13, 994–1002 (2006).

  107. 107.

    & Cytoplasmic functions of the tumour suppressor p53. Nature 458, 1127–1130 (2009).

  108. 108.

    Decision making by p53: life, death and cancer. Cell Death Differ. 10, 431–442 (2003).

  109. 109.

    et al. Control of signaling-mediated clearance of apoptotic cells by the tumor suppressor p53. Science 349, 1261669 (2015). This study demonstrates that p53-induced expression of DD1α is a vital phase for the phagocytic engulfment process of dead cells, which then facilitates the stepwise priming of immune surveillance.

  110. 110.

    & Cancer. A p53-regulated immune checkpoint relevant to cancer. Science 349, 476–477 (2015). This review summarizes a previously unrecognized function of p53: p53-induced expression of DD1α promotes the clearance of dead cells by promoting engulfment by macrophages. Expression of DD1α on T cells inhibits T cell function. Thus, p53 offers protection from inflammatory disease caused by the accumulation of apoptotic cells, and its suppression of T cells might help cancer cells to escape immune detection.

  111. 111.

    et al. Coinhibitory receptor PD-1H preferentially suppresses CD4(+) T cell-mediated immunity. J. Clin. Invest. 124, 1966–1975 (2014).

  112. 112.

    , , & Cutting edge: a monoclonal antibody specific for the programmed death-1 homolog prevents graft-versus-host disease in mouse models. J. Immunol. 187, 1537–1541 (2011).

  113. 113.

    et al. GI24 enhances tumor invasiveness by regulating cell surface membrane-type 1 matrix metalloproteinase. Cancer Sci. 101, 2368–2374 (2010).

  114. 114.

    et al. VISTA, a novel mouse Ig superfamily ligand that negatively regulates T cell responses. J. Exp. Med. 208, 577–592 (2011).

  115. 115.

    The blockade of immune checkpoints in cancer immunotherapy. Nat. Rev. Cancer 12, 252–264 (2012).

  116. 116.

    & Immune checkpoint targeting in cancer therapy: toward combination strategies with curative potential. Cell 161, 205–214 (2015).

  117. 117.

    , & PD-L1 (B7-H1) and PD-1 pathway blockade for cancer therapy: mechanisms, response biomarkers, and combinations. Sci. Transl. Med. 8, 328rv4 (2016).

  118. 118.

    et al. Analysis of immune signatures in longitudinal tumor samples yields insight into biomarkers of response and mechanisms of resistance to immune checkpoint blockade. Cancer Discov. 6, 827–837 (2016).

  119. 119.

    & Immune checkpoint protein inhibition for cancer: preclinical justification for CTLA-4 and PD-1 blockade and new combinations. Semin. Oncol. 42, 363–377 (2015).

  120. 120.

    , , & Coinhibitory pathways in immunotherapy for cancer. Annu. Rev. Immunol. 34, 539–573 (2016).

  121. 121.

    , , & PD-1 and BTLA and CD8(+) T-cell “exhaustion” in cancer: “exercising” an alternative viewpoint. Oncoimmunology 1, 735–738 (2012).

  122. 122.

    , & Beyond CTLA-4 and PD-1, the generation Z of negative checkpoint regulators. Front. Immunol. 6, 418 (2015).

  123. 123.

    et al. Irradiation and anti-PD-L1 treatment synergistically promote antitumor immunity in mice. J. Clin. Invest. 124, 687–695 (2014).

  124. 124.

    , & Prospects for TIM3-targeted antitumor immunotherapy. Cancer Res. 71, 6567–6571 (2011).

  125. 125.

    et al. LAG3 and PD1 co-inhibitory molecules collaborate to limit CD8+ T cell signaling and dampen antitumor immunity in a murine ovarian cancer model. Oncotarget 6, 27359–27377 (2015).

  126. 126.

    & Clinical blockade of PD1 and LAG3—potential mechanisms of action. Nat. Rev. Immunol. 15, 45–56 (2015).

  127. 127.

    et al. Synthetic lethality between Rb, 53 and Dicer or miR-17-92 in retinal progenitors suppresses retinoblastoma formation. Nat. Cell Biol. 14, 958–965 (2012).

  128. 128.

    et al. p53 represses c-Myc through induction of the tumor suppressor miR-145. Proc. Natl Acad. Sci. USA 106, 3207–3212 (2009).

  129. 129.

    et al. Modulation of microRNA processing by p53. Nature 460, 529–533 (2009).

  130. 130.

    et al. PDL1 Regulation by p53 via miR-34. J. Natl Cancer Inst. 108, djv303 (2016).

  131. 131.

    & Dendritic cells and the control of immunity. Nature 392, 245–252 (1998).

  132. 132.

    , & Dendritic cell and macrophage heterogeneity in vivo. Immunity 35, 323–335 (2011).

  133. 133.

    , , , & Epitope-specific regulation of memory programming by differential duration of antigen presentation to influenza-specific CD8(+) T cells. Immunity 41, 127–140 (2014).

  134. 134.

    , & The MDM2 inhibitor Nutlin-3 modulates dendritic cell-induced T cell proliferation. Hum. Immunol. 73, 342–345 (2012).

  135. 135.

    et al. Upregulation of major histocompatibility complex class I on liver cells by hepatitis C virus core protein via p53 and TAP1 impairs natural killer cell cytotoxicity. J. Virol. 77, 8299–8309 (2003).

  136. 136.

    , , & p53 increases MHC class I expression by upregulating the endoplasmic reticulum aminopeptidase ERAP1. Nat. Commun. 4, 2359 (2013).

  137. 137.

    , & The regulation of exosome secretion: a novel function of the p53 protein. Cancer Res. 66, 4795–4801 (2006).

  138. 138.

    et al. Dendritic cell derived-exosomes: biology and clinical implementations. J. Leukoc. Biol. 80, 471–478 (2006).

  139. 139.

    , & Dendritic-cell exosomes cross-present Toll-like receptor-ligands and activate bystander dendritic cells. Cell. Immunol. 289, 119–127 (2014).

  140. 140.

    et al. p53 and hTERT determine sensitivity to viral apoptosis. J. Virol. 81, 12985–12995 (2007).

  141. 141.

    & , , & p53 Attenuates lipopolysaccharide-induced NF-κB activation and acute lung injury. J. Immunol. 182, 5063–5071 (2009).

  142. 142.

    et al. p53 Integrates host defense and cell fate during bacterial pneumonia. J. Exp. Med. 210, 891–904 (2013).

  143. 143.

    & The Skp2 promoter integrates signaling through the NF-κB, 53, and Akt/GSK3β pathways to regulate autophagy and apoptosis. Mol. Cell 38, 524–538 (2010).

  144. 144.

    et al. p53 activates ICAM-1 (CD54) expression in an NF-κB-independent manner. EMBO J. 22, 1567–1578 (2003).

  145. 145.

    et al. Antiviral action of the tumor suppressor ARF. EMBO J. 25, 4284–4292 (2006).

  146. 146.

    et al. Activation of NF-κB pathway by virus infection requires Rb expression. PLoS ONE 4, e6422 (2009).

  147. 147.

    et al. The tumor suppressor PTEN has a critical role in antiviral innate immunity. Nat. Immunol. 17, 241–249 (2016).

  148. 148.

    , & Role of the retinoblastoma tumor suppressor in the maintenance of genome integrity. Curr. Mol. Med. 6, 749–757 (2006).

  149. 149.

    & RB: mitotic implications of a tumour suppressor. Nat. Rev. Cancer 12, 220–226 (2012).

  150. 150.

    et al. Loss of the retinoblastoma tumor suppressor: differential action on transcriptional programs related to cell cycle control and immune function. Oncogene 26, 6307–6318 (2007).

  151. 151.

    & Conserved functions of the pRB and E2F families. Nat. Rev. Mol. Cell. Biol. 9, 713–724 (2008).

  152. 152.

    & Tailoring to RB: tumour suppressor status and therapeutic response. Nat. Rev. Cancer 8, 714–724 (2008).

  153. 153.

    , & Emerging roles of E2Fs in cancer: an exit from cell cycle control. Nat. Rev. Cancer 9, 785–797 (2009).

  154. 154.

    & Molecular mechanisms underlying RB protein function. Nat. Rev. Mol. Cell. Biol. 14, 297–306 (2013).

  155. 155.

    , & The RB tumor suppressor at the intersection of proliferation and immunity: relevance to disease immune evasion and immunotherapy. Cell Cycle 14, 3812–3829 (2015).

  156. 156.

    et al. Rb/E2F1 regulates the innate immune receptor Toll-like receptor 3 in epithelial cells. Mol. Cell. Biol. 32, 1581–1590 (2012).

  157. 157.

    et al. Adenovirus small E1A employs the lysine acetylases p300/CBP and tumor suppressor Rb to repress select host genes and promote productive virus infection. Cell Host Microbe 16, 663–676 (2014).

  158. 158.

    et al. Retinoblastoma protein potentiates the innate immune response in hepatocytes: significance for hepatocellular carcinoma. Hepatology 60, 1231–1240 (2014).

  159. 159.

    , & E2F/Rb family proteins mediate interferon induced repression of adenovirus immediate early transcription to promote persistent viral infection. PLoS Pathog. 12, e1005415 (2016).

  160. 160.

    , & Regulation of T-cell responses by PTEN. Immunol. Rev. 224, 239–248 (2008).

  161. 161.

    & Lipid signaling in T-cell development and function. Cold Spring Harb. Perspect. Biol. 2, a002428 (2010).

  162. 162.

    et al. Impaired Fas response and autoimmunity in Pten+/− mice. Science 285, 2122–2125 (1999).

  163. 163.

    et al. The loss of PTEN allows TCR αβlineage thymocytes to bypass IL-7 and pre-TCR-mediated signaling. J. Exp. Med. 200, 883–894 (2004).

  164. 164.

    et al. Mutation of Pten/Mmac1 in mice causes neoplasia in multiple organ systems. Proc. Natl Acad. Sci. USA 96, 1563–1568 (1999).

  165. 165.

    et al. High cancer susceptibility and embryonic lethality associated with mutation of the PTEN tumor suppressor gene in mice. Curr. Biol. 8, 1169–1178 (1998).

  166. 166.

    et al. T cell-specific loss of Pten leads to defects in central and peripheral tolerance. Immunity 14, 523–534 (2001).

  167. 167.

    et al. Phosphatase and tensin homolog (PTEN) in antigen-presenting cells controls Th17- mediated autoimmune arthritis. Arthritis Res. Ther. 17, 230 (2015).

  168. 168.

    et al. Distinct roles for PTEN in prevention of T cell lymphoma and autoimmunity in mice. J. Clin. Invest. 120, 2497–2507 (2010). This study strongly suggests multiple and distinct regulatory roles for PTEN in the molecular pathogenesis of lymphoma and autoimmunity.

  169. 169.

    et al. Cutting edge: differential regulation of PTEN by TCR, Akt, and FoxO1 controls CD4+ T cell fate decisions. J. Immunol. 194, 4615–4619 (2015).

  170. 170.

    et al. Loss of PTEN promotes resistance to T cell-mediated immunotherapy. Cancer Discov. 6, 202–216 (2016).

  171. 171.

    , , , & Tumor suppression by ARF: gatekeeper and caretaker. Cell Cycle 9, 86–89 (2010).

  172. 172.

    & Tumor suppression by Ink4a-Arf: progress and puzzles. Curr. Opin. Genet. Dev. 13, 77–83 (2003).

  173. 173.

    E2F3-a novel repressor of the ARF/p53 pathway. Dev. Cell 6, 742–743 (2004).

  174. 174.

    Divorcing ARF and p53: an unsettled case. Nat. Rev. Cancer 6, 663–673 (2006).

  175. 175.

    , & The Arf/p53 pathway in cancer and aging. Cancer Res. 68, 6031–6034 (2008).

  176. 176.

    , & Macrophages, inflammation, and tumor suppressors: ARF, a new player in the game. Mediators Inflamm. 2012, 568783 (2012).

  177. 177.

    et al. p19(ARF) deficiency reduces macrophage and vascular smooth muscle cell apoptosis and aggravates atherosclerosis. J. Am. Coll. Cardiol. 55, 2258–2268 (2010).

  178. 178.

    et al. Loss of p14ARF in tumor cells facilitates replication of the adenovirus mutant dl1520 (ONYX-015). Nat. Med. 6, 1128–1233 (2000).

  179. 179.

    et al. Different requirements for the cytostatic and apoptotic effects of type I interferons. Induction of apoptosis requires ARF but not p53 in osteosarcoma cell lines. J. Biol. Chem. 279, 32275–32280 (2004).

  180. 180.

    , , & The tumor suppressor ARF regulates innate immune responses in mice. J. Immunol. 187, 6527–6538 (2011).

  181. 181.

    & Repair of strand breaks by homologous recombination. Cold Spring Harb. Perspect. Biol. 5, a012740 (2013).

  182. 182.

    “The race” to clone BRCA1. Science 343, 1462–1465 (2014).

  183. 183.

    , , & New York Breast Cancer Study Group. Breast and ovarian cancer risks due to inherited mutations in BRCA1 and BRCA2. Science 302, 643–646 (2003).

  184. 184.

    , , & Homologous recombination and human health: the roles of BRCA1, BRCA2, and associated proteins. Cold Spring Harb. Perspect. Biol. 7, a016600 (2015).

  185. 185.

    et al. BRCA1 regulates IFN-γ signaling through a mechanism involving the type I IFNs. Mol. Cancer Res. 5, 261–270 (2007).

  186. 186.

    et al. CTLA-4 blockade synergizes therapeutically with PARP inhibition in BRCA1-deficient ovarian cancer. Cancer Immunol. Res. 3, 1257–1268 (2015).

  187. 187.

    , , , & Brca2 deficiency leads to T cell loss and immune dysfunction. Mol. Cells 38, 251–258 (2015).

  188. 188.

    et al. Association and prognostic significance of BRCA1/2-mutation status with neoantigen load, number of tumor-infiltrating lymphocytes and expression of PD-1/PD-L1 in high grade serous ovarian cancer. Oncotarget 7, 13587–13598 (2016).

  189. 189.

    , & Melanoma-intrinsic β-catenin signaling prevents anti-tumour immunity. Nature 523, 231–235 (2015).

  190. 190.

    et al. MYC regulates the antitumor immune responses through CD47 and PD-L1. Science 352, 227–231 (2016).

  191. 191.

    , & MYC - a thorn in the side of cancer immunity. Cell Res. 26, 639–640 (2016).

Download references

Acknowledgements

The authors thank the members of the Lee laboratory for their helpful discussions. This work is supported by the grants 1RO1CA195534, 1R01CA203552, PO1CA80058, MGH ECOR funding, and the Breast Cancer Research Foundation.

Author information

Affiliations

  1. Heinrich Pette Institute, Leibniz Institute for Experimental Virology, Martinistrasse 52, 20251 Hamburg, Germany.

    • César Muñoz-Fontela
  2. Cutaneous Biology Research Center, Massachusetts General Hospital and Harvard Medical School, Building 149 13th Street, Charlestown, Massachusetts 02129, USA.

    • Anna Mandinova
    •  & Sam W. Lee
  3. Harvard Stem Cell Institute, 7 Divinity Avenue, Cambridge, Massachusetts 02138, USA.

    • Anna Mandinova
  4. Broad Institute of Harvard and MIT, 7 Cambridge Center, Cambridge, Massachusetts 02142, USA.

    • Anna Mandinova
    •  & Sam W. Lee
  5. Department of Oncological Sciences, Mount Sinai School of Medicine, One Gustave L. Levy Place, New York, New York 10029, USA.

    • Stuart A. Aaronson

Authors

  1. Search for César Muñoz-Fontela in:

  2. Search for Anna Mandinova in:

  3. Search for Stuart A. Aaronson in:

  4. Search for Sam W. Lee in:

Competing interests

The authors declare no competing financial interests.

Corresponding authors

Correspondence to Stuart A. Aaronson or Sam W. Lee.

Glossary

ARF–p53 tumour suppressor pathway

ARF regulates p53 activity through the direct binding to MDM2 to neutralize its function, which initiates transcription factor activity of p53. The ARF–p53 axis is essential for the detection and removal of damaged cells, and the inactivation of ARF and p53 occurs in a mutually exclusive manner in human cancers.

Immune checkpoint pathways

Immune checkpoints are used by the host to regulate immune responses and prevent immune hyperactivation from harming normal tissues.

'Eat-me' signal

Apoptotic cells expose markers known as eat-me signals on their surface that are recognized by phagocytes through specific engulfment receptors.

Congenital retinoblastoma

Congenital retinoblastoma is the most common eye tumour in children and the third most common cancer overall affecting children; it is caused by a germline mutation in RB1.

About this article

Publication history

Published

DOI

https://doi.org/10.1038/nri.2016.99

Further reading